Aprea Therapeutics doses first patient in Phase 1 trial of oral WEE1 inhibitor APR-1051

Aprea Therapeutics, Inc.

First patient dosed in ACESOT-1051 Phase 1 trial of oral WEE1 inhibitor APR-1051 as monotherapy in advanced solid tumors.
APR-1051 is a potent, highly selective WEE1 inhibitor designed to limit off-target PLK inhibition and improve PK profile.
Trial targets tumors with CCNE1/2 amplification, FBXW7/PPP2R1A mutations, KRAS-G12/TP53 co-mutated CRC, or uterine serous carcinoma.
Dose escalation (up to 39 patients) and dose optimization (up to 40 patients) to determine RP2D; first site at NEXT Oncology (San Antonio).
Company expects clinical update by year-end 2024 and preliminary efficacy data in 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.